mainz,Rhineland-Palatinate /germany – 16 07 2022: the biontech company building and flags in mainz germany | Image Credit: © Tobias Arhelger – stock.adobe.com
In a move to reportedly consolidate and expand its capabilities in messenger RNA (mRNA)-based medicine, BioNTech has announced plans to acquire CureVac through an all-stock transaction valued at approximately $1.25 billion (1). The acquisition aims to accelerate the development and manufacturing of next-generation mRNA immunotherapies for oncology and infectious diseases by combining the strengths of the two German-based biotechnology companies.
